Rituximab as First Choice for Patients With Refractory Rheumatoid Arthritis: Cost-Effectiveness Analysis in Iran Based on a Systematic Review and Meta-Analysis
Value in Health - United Kingdom
doi 10.1016/j.jval.2014.08.2623
Full Text
Open PDFAbstract
Available in full text
Date
November 1, 2014
Authors
Publisher
Elsevier BV